DeepMed Research

ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assessment of Alcon's Ocular Image Quantification System

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
Other: Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)

First Posted Date: 2011-01-24

Last Posted Date: 2012-12-18

Lead Sponsor: Alcon Research

Target Recruit Count: 13

Registration Number: NCT01282138

Locations: 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

Phase 2

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Difluprednate 0.05% ophthalmic emulsion
Other: Difluprednate vehicle

First Posted Date: 2011-01-13

Last Posted Date: 2013-03-11

Lead Sponsor: Alcon Research

Target Recruit Count: 722

Registration Number: NCT01276223

Locations: 🇺🇸
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations, Fort Worth, Texas, United States

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Phase 4

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

First Posted Date: 2011-01-07

Last Posted Date: 2012-09-18

Lead Sponsor: Alcon Research

Target Recruit Count: 300

Registration Number: NCT01272089

Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Brinzolamide 1% / timolol 0.5% Fixed Combination
Drug: Habitual prostaglandin monotherapy

First Posted Date: 2010-12-20

Last Posted Date: 2014-05-20

Lead Sponsor: Alcon Research

Target Recruit Count: 47

Registration Number: NCT01263444

A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)

Not Applicable

Completed

Conditions: Cataract

Interventions: Device: Acri.LISA® 366D IOL
Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1
Device: Acri.LISA® 466TD Toric IOL
Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT

First Posted Date: 2010-12-09

Last Posted Date: 2018-07-02

Lead Sponsor: Alcon Research

Target Recruit Count: 31

Registration Number: NCT01257217

Evaluation of Silicone Hydrogel Lens Wettability With Marketed Lens Care Solutions

Not Applicable

Completed

Conditions: Contact Lens Wear

Interventions: Device: Biotrue multipurpose solution
Device: Sauflon Synergi multipurpose solution
Device: OTE Elements multipurpose solution
Device: Silicone hydrogel contact lenses (Acuvue Advance)

First Posted Date: 2010-12-02

Last Posted Date: 2012-06-11

Lead Sponsor: Alcon Research

Target Recruit Count: 22

Registration Number: NCT01252134

Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Other: Systane Ultra Lubricant Eye Drops
Other: Hialid 0.1 Artificial Tears Eye Drops
Other: Unisol 4 Saline Solution

First Posted Date: 2010-12-02

Last Posted Date: 2012-10-30

Lead Sponsor: Alcon Research

Target Recruit Count: 27

Registration Number: NCT01252121

Clinical Performance of a Silicone Hydrogel Lens With Use of FID 114675A

Not Applicable

Completed

Conditions: Contact Lens Fit
Myopia

Interventions: Device: FID 114675A multi-purpose disinfecting solution (MPDS)
Device: renu fresh Multi-Purpose Solution (MPS)
Device: Galyfilcon A contact lenses (Acuvue Advance)

First Posted Date: 2010-11-15

Last Posted Date: 2012-07-12

Lead Sponsor: Alcon Research

Target Recruit Count: 89

Registration Number: NCT01240135

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Phase 2

Withdrawn

Conditions: Bacterial Conjunctivitis

Interventions: Drug: AL-6515 0.3%
Drug: Vehicle
Drug: AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension
Drug: AL-15469A 0.5%

First Posted Date: 2010-11-11

Last Posted Date: 2011-12-01

Lead Sponsor: Alcon Research

Registration Number: NCT01238783

Safety and Efficacy of Changing to DuoTrav From Prior Therapy

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)

First Posted Date: 2010-10-29

Last Posted Date: 2016-11-21

Lead Sponsor: Alcon Research

Target Recruit Count: 105

Registration Number: NCT01230736

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy